A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Sponsor
Qilu Hospital of Shandong University
Study ID
NCT06300216
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Octreotide microspheres — DRUG
    20mg/30mg Q4W

Study Details

The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.

Key Dates

First listed
Mar 8, 2024
Start date
Mar 26, 2024
Status verified
Feb 2024
Primary completion
Nov 26, 2027
Completion
May 26, 2028

Study Design

Enrollment
500 participants (estimated)

Arms

  • Arm: Octreotide microspheres standard dose monotherapy
  • Arm: Octreotide microspheres standard dose combination therapy
  • Arm: Octreotide microspheres incremental or increased frequency therapy
  • Arm: Octreotide microspheres maintenance therapy after targeted or chemotherapy

Primary Outcome Measure

Treatment Emergent Adverse Events [ Time Frame: up to 46 months ]

Central Contacts

Find similar trials

Nationwide
Neuroendocrine tumors trialsOncology trials

Related Studies